Nadim Ahmed
Fortuna: 2 M $ al 30/06/2026
Fortuna: 2 M $ al 30/06/2026
Mr. Nadim Ahmed is a President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc., a President, Chief Executive Officer & Director at Cullinan Mica Corp.
and a President, Chief Executive Officer & Director at Cullinan Pearl Corp.
He is on the Board of Directors at Disc Medicine, Inc., Cullinan Therapeutics, Inc., Family Promise, Cullinan Mica Corp.
and Cullinan Pearl Corp.
Mr. Ahmed was previously employed as a President, Chief Executive Officer & Director by Cullinan Oncology LLC, a President-Hematology by Bristol Myers Squibb Co., a President-Global Hematology & Oncology by Celgene Corp., and a Senior Marketing Director-Hematologic Oncology by GlaxoSmithKline LLC.
He received his undergraduate degree from the University College London and a graduate degree from Loughborough University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/04/2026 | 135.921 ( 0,23 % ) | 2 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Director Ejecutivo | 18/10/2021 |
| DISC MEDICINE, INC. | Director/Miembro de la Junta | 14/07/2025 |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Director/Miembro de la Junta | - |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Director Ejecutivo | - |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Director Ejecutivo | - |
| Empresas | Cargo | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2021 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01/03/2010 |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Director Ejecutivo | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.